The COVID-19 vaccine market is expected to be valued at $10 billion a year across developed countries based on analyst estimates from Morgan Stanley and Credit Suisse. An analyst from Credit Suisse even expects that the market could be worth more than $10 billion in the United States alone. In recent news, vaccine candidates from Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca have shown high efficacy rates, with Pfizer leading the pack as it obtained approval from the UK and Canada for mass rollout. The COVID-19 vaccine race might be already declaring its frontrunners in the coming months, and we deem it necessary to look at the patent landscape these pharma giants are operating in.
Download our FREE Patent Landscape Report